Good news for multiple myeloma patients. At ASH21 it was hailed as the discover that will put multiple myeloma specialist out of work.
Not sure how it impacts RAC
Due for FDA approval in Feb 2022
https://www.cancernetwork.com/view/second-line-cilta-cel-yields-strong-responses-and-encouraging-mrd-negativity-for-early-relapse-myeloma
Good news for multiple myeloma patients. At ASH21 it was hailed...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.50 |
Change
0.010(0.67%) |
Mkt cap ! $249.1M | |||
| Open | High | Low | Value | Volume |
| $1.51 | $1.53 | $1.48 | $91.85K | 61.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 934 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 287 | 1 |
View Market Depth
| Last trade - 11.30am 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.50 |
Change
0.010 ( 0.18 %) |
||||
| Open | High | Low | Volume | ||
| $1.52 | $1.52 | $1.48 | 6996 | ||
| Last updated 11.30am 21/05/2024 ? | |||||
| RAC (ASX) Chart |